HAEMONETICS CORP's ticker is HAE and the CUSIP is 405024100. A total of 288 filers reported holding HAEMONETICS CORP in Q4 2020. The put-call ratio across all filers is 1.18 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $354,647 | +5.7% | 3,959 | +0.5% | 0.01% | +9.1% |
| Q2 2023 | $335,367 | +2.9% | 3,939 | 0.0% | 0.01% | 0.0% |
| Q1 2023 | $325,952 | +106073.3% | 3,939 | +0.8% | 0.01% | 0.0% |
| Q4 2022 | $307 | -99.9% | 3,909 | 0.0% | 0.01% | 0.0% |
| Q3 2022 | $290,000 | +13.7% | 3,909 | -0.4% | 0.01% | +22.2% |
| Q2 2022 | $255,000 | +3.7% | 3,926 | +1.0% | 0.01% | +12.5% |
| Q1 2022 | $246,000 | +18.3% | 3,888 | -0.9% | 0.01% | +33.3% |
| Q4 2021 | $208,000 | -24.9% | 3,923 | -0.0% | 0.01% | -45.5% |
| Q3 2021 | $277,000 | +5.3% | 3,924 | -0.8% | 0.01% | 0.0% |
| Q2 2021 | $263,000 | -64.1% | 3,955 | -40.1% | 0.01% | -65.6% |
| Q1 2021 | $732,000 | -6.9% | 6,600 | -0.3% | 0.03% | -11.1% |
| Q4 2020 | $786,000 | +228.9% | 6,617 | +141.9% | 0.04% | +200.0% |
| Q3 2020 | $239,000 | +305.1% | 2,735 | +363.6% | 0.01% | +200.0% |
| Q4 2018 | $59,000 | -35.2% | 590 | -25.8% | 0.00% | -20.0% |
| Q3 2018 | $91,000 | – | 795 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Millrace Asset Group, Inc. | 19,264 | $1,726 | 2.13% |
| Parkman Healthcare Partners LLC | 88,962 | $7,969,216 | 1.46% |
| HEARTLAND ADVISORS INC | 256,414 | $24,435,274 | 1.37% |
| Riverwater Partners LLC | 15,553 | $1,393,238 | 1.27% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 111,100 | $9,952,338 | 1.15% |
| Lisanti Capital Growth, LLC | 78,425 | $7,025,312 | 1.11% |
| Aristotle Capital Boston, LLC | 311,666 | $27,919,054 | 0.90% |
| ROYCE & ASSOCIATES LP | 947,550 | $84,881,529 | 0.86% |
| CHASE INVESTMENT COUNSEL CORP | 18,770 | $1,681 | 0.84% |
| Virtus Investment Advisers, Inc. | 13,662 | $1,223,842 | 0.83% |